Weekly Recap: >50% specialty sales target and bepirovirsen 19% cure
GSK plc Sponsored ADR (LSE:GSK) is pivoting toward specialty medicines—targeting >50% sales by 2031 with higher R&D and productivity cuts—while advancing key drugs: bepirovirsen shows a 19% HBV cure rate, Jemperli and Blenrep seek expanded approvals/access, and Excentia faces U.S. payer hurdles.Pre…